Fairvalue-Calculator Fairvalue-Calculator
EN DE

PD-Rx Pharmaceuticals, Inc (PDRX) Fair Value & Analysis

Healthcare · US · Market cap $5.7M

Price$3.35
Fair Value$9.38
Upside+180.0%
Quality95/100
Evidence: Medium Range $7.64 – $11.11

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

PD-Rx Pharmaceuticals, Inc (PDRX) currently trades at $3.35, while our model-based Fair Value estimate is $9.38 — implying the stock looks roughly 180.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company offers prepackaged medications, such as creams, ointments, ophthalmics, otics, liquids, and suspension products. It also provides packaging services. In addition, the company offers a dispensing platform, a manual dispensing system that provides 10 recordkeeping labels to match the 10 bottle trays as a handling package; and PD-Rx Net, a web-based application designed to track prescriptions filled at the point of care and print prescription labels for prescriptions that are filled onsite. Further, it provides primary care, urgent care, pain management, occupational and orthopedic medicine, bariatric, dental, and other physician dispensing services. The company serves the governmental, commercial, and point-of-care pharmaceutical industry. PD-Rx Pharmaceuticals, Inc. was incorporated in 1986 and is based in Oklahom…

Open the full interactive analysis →

Similar stocks

McKesson Corporation (M1CK34) +24% Cencora, Inc (C1CO34) -44% Cardinal Health, Inc (CAH) -54% Sigma Healthcare Limited (SIGGF) -67% Sitka Gold Corp (SIG) -88% Shanghai Pharmaceuticals Holding (601607) +112%

Frequently asked questions

Is PD-Rx Pharmaceuticals, Inc (PDRX) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $9.38 versus a price of $3.35 — about +180% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PDRX?
Our 21-model fair value for PD-Rx Pharmaceuticals, Inc is $9.38 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.35.
What is the quality score of PDRX?
PD-Rx Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.